SCHEMBL5116245

SCHEMBL5116245

Fc1ccc(CNc2nc(-n3cncn3)nc3sc(Cl)cc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 1/20 0.41
KDM4E B2RXH2 2/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
PDE10A Q9Y233 1/20 0.38
USP10 Q14694 1/20 0.37
PIK3C3 Q8NEB9 1/20 0.37
USP13 Q92995 1/20 0.37
TP53 P04637 2/20 0.36
ABL1 P00519 1/20 0.36
FYN P06241 1/20 0.36
SRC P12931 1/20 0.36
FLT3 P36888 1/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 1/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
APP P05067 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5127643 0.89 PDE5A (0.45) HRH4KDM4EMAPK1PDE10AMAPT
SCHEMBL5125114 0.88 PDE10A (0.38) PDE10AABL1SRCPDE5AUSP1
SCHEMBL5123695 0.88 HRH4 (0.39) HRH4KDM4ETSHRMAPK1HSD17B10
SCHEMBL5122122 0.86 ICAM1 (0.47) HRH4KDM4ETSHRMAPK1HSD17B10
SCHEMBL5130913 0.86 KDM4E (0.44) HRH4KDM4ETSHRMAPK1HSD17B10
SCHEMBL5123682 0.85 HRH4 (0.41) HRH4MAPK1USP10PIK3C3USP13
SCHEMBL5118460 0.83 PDE5A (0.53) HRH4PDE5A
SCHEMBL5116266 0.83 TNF (0.45) TSHRMEN1KMT2AAPPPDE5A
SCHEMBL5121860 0.83 HTT (0.40) HRH4KDM4ETSHRMAPK1HSD17B10
SCHEMBL5120241 0.82 BCDIN3D (0.45) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 HRH4 1479/4885KDM4E 257/4885TSHR 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.